Significant difference in ILD incident between the FXa inhibitor vs warfarin groups remained (0.30 vs 0.17 per 100 patient-years; HR, 1.56 [95% CI, 1.23-1.97]; P < .001). This evidence concerns the gene F10 and interstitial lung disease.